National Cancer Research Institute (NCRI) Annual Conference - poster presentations and a prize winner


This year's annual NCRI conference starts on Sunday 1st November and runs until Weds 4th November in Liverpool. OCTO (the oncology division of OCTRU) and CSM have worked together on several trials which will be presented as posters at this year's conference:

DOC-MEK: A phase 2 trial of docetaxel with or without AZD6244 in wt BRAF melanoma

RADVAN: A randomized phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases

CHOP-OR: Multi-centre non-randomised Phase II feasibility study of Ofatumumab in combination with CHOP in induction/consolidation followed by Ofatumumab maintenance every 2 months for one year in patients with biopsy proven Richter's Syndrome

6MP: A Phase II Clinical Trial Of 6-Mercaptopurine and low-dose Methotrexate in Patients with BRCA Defective Tumours

DEBIOC: A Phase I dose escalating study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma

BKM-120: A phase I study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy.

SCALOP-2: A multi‐centre randomised study of induction chemotherapy followed by capecitabine (+/‐nelfinavir) with high or standard dose radiotherapy for locally advanced non‐metastatic pancreatic cancer

Dr Avinash Gupta has been awarded the McElwain Prize by the Association of Cancer Physicians for his research based on the DOC-MEK study. Dr Gupta was a key member of both the DOC-MEK trial management group and as part of the clinical site team at the Early Phase Clinical Trials Unit at the Churchill Hospital, Oxford.